A double‐blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy

@article{Castro1971ADC,
  title={A double‐blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy},
  author={J. Castro and Henry Joseph Griffiths and D E Edwards},
  journal={British Journal of Surgery},
  year={1971},
  volume={58}
}
A double‐blind, controlled, clinical trial of spironolactone (Aldactone‐A), 50 mg. b. d., showed this to be better than a placebo for the short‐term treatment of benign prostatic hypertrophy, although the advantage was not maintained over a longer period of time. There was considerable response to the placebo and the importance of comparative trials with objective measurements is discussed. 
Candicidin in treatment of benign prostatic hypertrophy.
In a prospective, double-blind, placebo-controlled multicenter study, candicidin (a polyene macrolide) was investigated in the treatment of benign prostatic hypertrophy. Seventy-six patients wereExpand
The effect of bromocriptine in patients with benign prostatic hypertrophy.
TLDR
A double blind trial of bromocriptine in the treatment of 14 patients with the symptoms of benign prostatic hypertrophy results in symptomatic improvement in 6, with objective evidence of improvement in 3 patients on flow rate measurements. Expand
Symptomatic treatment of benign prostatic obstruction with Nicergoline: A placebo controlled clinical study and urodynamic evaluation
TLDR
Nicergoline seems to be active and well tolerated in the treatment of benign prostatic obstruction and the “irritative” symptoms of prostatic hypertrophy were improved after Nicergoline significantly more than after placebo. Expand
Evaluation of a synthetic vasopressin analogue for treatment of nocturia in benign prostatic hypertrophy. A double-blind study.
TLDR
Though the frequency of nocturnal micturition fell in 13 patients, only 7 were considered to give a good clinical response, and this drug can be tried in patients with benign prostatic hypertrophy if nocturia is distressing and the patient is unsuitable or disinclined for surgery. Expand
A double blind trial of a polyene macrolide--nystatin--in the treatment of benign prostatic hyperplasia in man.
TLDR
In a double blind trial of 6 weeks' duration nystatin in doses of 500,000 units 8–hourly when taken orally was without effect when compared with a placebo. Expand
Flutamide in treatment of benign prostatic hypertrophy.
TLDR
Flutamide may be a safe and effective drug for the treatment of symptomatic BPH and significant symptomatic improvements were noted in both groups. Expand
Candicidin treatment of prostatism: A prospective double-blind placebo-controlled study
TLDR
Candicidin appears valuable in the treatment of BPH patients who are a poor surgical risk and positive results are much less pronounced than those obtained with surgery. Expand
ENDOCRINE EFFECTS OF SPIRONOLACTONE IN MAN
TLDR
It is concluded that treatment with spironolactone for 2–4 days will lead to a transient rise in plasma T and urinary DHA, accompanied by increased androgen catabolism and a slightly increased conversion of androgens to oestrogens. Expand
Nonsurgical treatment of benign prostatic hypertrophy
  • P. Ekman
  • Medicine
  • World Journal of Urology
  • 2004
TLDR
Endocrine therapy appears to be effective in reducing prostate size and hence improving urinary outflow, and a combination of progestational antiandrogens and antiprolactin seems to be an efficient remedy for symptoms of prostatism when surgery is not applicable or wanted. Expand
The response of the benign hypertrophied prostate to endocrine therapy
Histological evidence of benign prostatic hypertrophy (BPH) can be found in the prostates of almost all men as they exceed the age of 40. The true incidence is difficult to determine as mostExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION.
TLDR
Medical prophylaxis capable of preventing this condition or of arresting its progress would be more useful than surgery for treatment of benign prostatic hypertrophy. Expand
A Study of Endocrine Function in the Treatment of Benign Prostatic Hypertrophy with Megestrol Acetate
TLDR
The aetiology of BPH has been the subject of many clinical studies and animal experiments but no final conclusions have been arrived at as yet and some of the difficulties encountered arise because of the differences in the development and function of the prostate between one species and another. Expand
Evaluation of Hydroxyprogesterone Caproate in the Treatment of Benign Prostatic Hyperplasia
These investigators have found no clear-cut evidence that this hormone is beneficial in the treatment of benign prostatic hyperplasia.
Significance of Signs and Symptoms in Benign Prostatic Hypertrophy
Measurements of intravesical pressure, urinary flow rate, retrograde cystographic residual urine, reflux of contrast medium into the prostatic ducts, and radiological prostate size were made in 45Expand
ESTROGENIC MANAGEMENT OF BENIGN PROSTATISM, INCLUDING EARLY AND POOR‐RISK CASES: 7‐YEAR EXPERIENCE *
  • H. J. Roberts
  • Medicine
  • Journal of the American Geriatrics Society
  • 1966
TLDR
The adminit-:tration of estrogens, orally or intravenously, repeatedly has proved of value in managing patients with such complicated problems and the need for effective, rational and safe medical treatment of benign prostatism is underscored. Expand
An evaluation of the importance of residual urine.
TLDR
There was a poor statistical correlation with both urine flow and urethral resistance but there was a close correlation between the radiological post micturition residue and its actual volume measured by catheterisation. Expand
Surgical Pathology of Prostatic Obstructions
TLDR
The purpose of the monograph is stated to be fourfold: an analysis of the material at hand under the headings of hypertrophy, median bar, carcinoma and abscess; the study of the gross morbid findings; the surgical handling of such cases; and the provision of a series of illustrations depicting the actual specimens. Expand
RADIOGRAPHIC ESTIMATION OF THE SIZE OF THE PROSTATE.
Because open prostatic surgery is not a completely lost art and because some urologists still perform both open prostatic surgery and transurethral prostatic resections, the size of the obstructingExpand
Concepts of urethral resistance.
TLDR
It is recommended that the calculated effective urethral cross-sectional area as derived from the formula A=1.14 F/P be adopted as the most satisfactory measure of outflow tract obstruction. Expand
Estimation of Plasma Phosphatase by Determination of Hydrolysed Phenol with Amino-antipyrine
TLDR
The conditions under which enzymic hydrolysis is carried out are the same as in the King-Armstrong method, as modified by King (1951), the amino-antipyrine reagent (A.A.P.) being used to estimate the phenol liberated. Expand
...
1
2
3
...